stk11/ keap1 co-mutant lung adenocarcinoma is dependent on scd1 to evade ferroptosis
Published 3 years ago • 352 plays • Length 4:09Download video MP4
Download video MP3
Similar videos
-
0:35
data on kras inhibitors in lung cancer at wclc 2022
-
1:18
what is the stk11 mutation?
-
0:41
unmet needs in kras-driven non-small cell lung cancer
-
1:37
treatment strategies for kras-mutant nsclc with co-mutations
-
1:11
dr. jacob kaufman: unlocking the secrets of stk11 mutations in lung cancer
-
13:45
case review: io-based therapy in kras-, stk11, or keap mutated nsclc?
-
3:41
impact of coalterations on kras-mutant nsclc
-
0:47
the role of immunotherapy with kras inhibitors in kras-driven nsclc
-
1:10
targeting non-g12c kras mutations in nsclc
-
5:53
asco 2019 lc roundtable - stk11 keap as targets -should results enter into clinical decision making?
-
2:42
codebreak 200: sotorasib versus docetaxel in pretreated kras g12c-mutant nsclc
-
2:49
case 2: stage iv pd-l1–negative, kras-mutant lung adenocarcinoma
-
6:59
case 2: diagnosing pd-l1 and egfr lung adenocarcinoma
-
9:30
lineage plasticity in lung cancer: biological & therapeutic implications
-
0:44
com503: the next steps in harnessing cytokines to treat cancer
-
4:37
surgical vs endoscopic management of t1 esophageal adenocarcinoma
-
0:24
hbd 011 bauchspeicheldrüse krebsbhandlung - sd pal /hbd 011 pankreas tumor treatment - sd pal
-
0:39
daniel petrylak, md, on the current role of ctc tumor cell components via liquid biopsy pc treatment